Sanofi is paying Regeneron $1 billion upfront to collaborate on four early-stage im | Sanofi is paying Regeneron $1 billion ...

As Foghorn digested the end of the Lilly partnership, the biotech said it was laying off 40% of its workforce, while “further ...

The revelation of a patient death in Bristol Myers Squibb’s phase 3 trial of a potential pulmonary fibrosis treatment has ...

A more subdued volume of biopharma layoffs continued into the third quarter of 2026, validating predictions that the sector ...

When recombinant DNA expert Herbert Boyer, Ph.D., first got a call from venture capitalist Robert Swanson about starting a ...

Eli Lilly has shared detailed data from a phase 3 retatrutide trial, revealing that more than one-third of patients on the ...

Eli Lilly has tied its amylin-Zepbound combination treatment eloraTZP to 23.3% average weight loss in patients struggling ...

The Danish drugmaker is paying $300 million upfront to China’s Hengrui Pharma for a preclinical GLP-1/GIP dual receptor ...

Merck touted a win for its anti-TL1A antibody in a phase 2b trial in patients with moderate to severe hidradenitis ...

Base editing biotech Beam Therapeutics is suing one of its newest rivals, alleging that the upstart company stole the secrets ...

GSK is paying Wave Life Sciences $12 million upfront to take ownership of a hepatic program arising from the companies’ ...

Connect Biopharma has pointed to phase 2 data for its IL-4/IL-13 blocker as proof that the wannabe Dupixent rival can reduce ...